[A24-50] Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V

Last updated 01.08.2024

Project no.:
A24-50

Commission:
Commission awarded on 30.04.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Haematology

Indication:

Adults with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS)

  • who have not yet received and who are eligible for erythropoiesis-stimulating agent-based therapy
  • without ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agent-based therapy
Result of dossier assessment:

Patients:

  • who have not yet received and who are eligible for erythropoiesis-stimulating agent-based therapy: added benefit not proven
  • without ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agent-based therapy: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://dx.doi.org/10.60584/A24-50

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form